ReviewAnnals of hematology2024

CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia.

Abdulfatah M Alayoubi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.